PE20212067A1 - Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada - Google Patents
Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratadaInfo
- Publication number
- PE20212067A1 PE20212067A1 PE2021001372A PE2021001372A PE20212067A1 PE 20212067 A1 PE20212067 A1 PE 20212067A1 PE 2021001372 A PE2021001372 A PE 2021001372A PE 2021001372 A PE2021001372 A PE 2021001372A PE 20212067 A1 PE20212067 A1 PE 20212067A1
- Authority
- PE
- Peru
- Prior art keywords
- trifluoromethyl
- crystalline form
- dihydroisoquinolin
- carboxamide
- pyridin
- Prior art date
Links
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 title 2
- 229940126062 Compound A Drugs 0.000 abstract 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 2
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229940122339 MALT1 inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019075834 | 2019-02-22 | ||
| PCT/EP2020/054485 WO2020169736A1 (en) | 2019-02-22 | 2020-02-20 | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212067A1 true PE20212067A1 (es) | 2021-10-26 |
Family
ID=69723907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001372A PE20212067A1 (es) | 2019-02-22 | 2020-02-20 | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12269813B2 (https=) |
| EP (1) | EP3927696B1 (https=) |
| JP (1) | JP2022523368A (https=) |
| KR (1) | KR20210131371A (https=) |
| CN (1) | CN113474339B (https=) |
| AU (1) | AU2020226723B2 (https=) |
| BR (1) | BR112021016400A2 (https=) |
| CA (1) | CA3129623A1 (https=) |
| EA (1) | EA202192320A1 (https=) |
| EC (1) | ECSP21067828A (https=) |
| ES (1) | ES2966132T3 (https=) |
| IL (1) | IL285675A (https=) |
| JO (1) | JOP20210227A1 (https=) |
| MA (1) | MA55019A (https=) |
| MX (1) | MX2021010133A (https=) |
| PE (1) | PE20212067A1 (https=) |
| PH (1) | PH12021552018A1 (https=) |
| SG (1) | SG11202108909SA (https=) |
| TW (1) | TW202045495A (https=) |
| UY (1) | UY38592A (https=) |
| WO (1) | WO2020169736A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| TW202227067A (zh) | 2020-08-21 | 2022-07-16 | 比利時商健生藥品公司 | Ｍａｌｔ１抑制劑之無定形形式及其配製物 |
| BR112023017648A2 (pt) | 2021-03-03 | 2023-11-14 | Janssen Pharmaceutica Nv | Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk |
| BR112023017689A2 (pt) | 2021-03-03 | 2023-11-14 | Janssen Pharmaceutica Nv | Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida) |
| MX2024001840A (es) | 2021-08-09 | 2024-02-28 | Janssen Pharmaceutica Nv | Composiciones para usar en el tratamiento de neoplasias de celulas b. |
| WO2025073968A1 (en) | 2023-10-06 | 2025-04-10 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098515A2 (en) | 2003-04-30 | 2004-11-18 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer |
| JP2009533327A (ja) * | 2006-03-22 | 2009-09-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤 |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| WO2011036885A1 (ja) * | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| ES2539379T3 (es) | 2010-06-22 | 2015-06-30 | Basf Se | Procedimiento de preparación de 4-hidroxipiridinas |
| JP6231085B2 (ja) * | 2012-05-31 | 2017-11-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | アミノキナゾリン誘導体及びピリドピリミジン誘導体 |
| SG11201607895PA (en) | 2014-05-28 | 2016-12-29 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
| AU2015300966A1 (en) | 2014-08-08 | 2017-02-16 | Janssen Pharmaceutica Nv | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| WO2016209688A1 (en) * | 2015-06-24 | 2016-12-29 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of cancer and uses thereof |
| AU2016352813B2 (en) | 2015-11-13 | 2019-09-19 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| US10882841B2 (en) | 2016-03-01 | 2021-01-05 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| TWI795381B (zh) * | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| AU2018395291A1 (en) | 2017-12-28 | 2020-07-30 | The General Hospital Corporation | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment |
| EP3756268A1 (de) | 2018-02-23 | 2020-12-30 | Industrieanlagen-Betriebsgesellschaft mbH | Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen |
| WO2021138298A1 (en) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| TW202227067A (zh) * | 2020-08-21 | 2022-07-16 | 比利時商健生藥品公司 | Ｍａｌｔ１抑制劑之無定形形式及其配製物 |
-
2020
- 2020-02-20 US US17/431,447 patent/US12269813B2/en active Active
- 2020-02-20 MA MA055019A patent/MA55019A/fr unknown
- 2020-02-20 PE PE2021001372A patent/PE20212067A1/es unknown
- 2020-02-20 MX MX2021010133A patent/MX2021010133A/es unknown
- 2020-02-20 ES ES20707585T patent/ES2966132T3/es active Active
- 2020-02-20 CA CA3129623A patent/CA3129623A1/en active Pending
- 2020-02-20 CN CN202080015968.5A patent/CN113474339B/zh active Active
- 2020-02-20 AU AU2020226723A patent/AU2020226723B2/en not_active Expired - Fee Related
- 2020-02-20 BR BR112021016400-6A patent/BR112021016400A2/pt not_active Application Discontinuation
- 2020-02-20 KR KR1020217029765A patent/KR20210131371A/ko not_active Withdrawn
- 2020-02-20 EA EA202192320A patent/EA202192320A1/ru unknown
- 2020-02-20 WO PCT/EP2020/054485 patent/WO2020169736A1/en not_active Ceased
- 2020-02-20 JP JP2021549407A patent/JP2022523368A/ja active Pending
- 2020-02-20 SG SG11202108909SA patent/SG11202108909SA/en unknown
- 2020-02-20 PH PH1/2021/552018A patent/PH12021552018A1/en unknown
- 2020-02-20 EP EP20707585.4A patent/EP3927696B1/en active Active
- 2020-02-21 TW TW109105620A patent/TW202045495A/zh unknown
- 2020-02-21 UY UY0001038592A patent/UY38592A/es unknown
-
2021
- 2021-08-17 IL IL285675A patent/IL285675A/en unknown
- 2021-08-18 JO JOP/2021/0227A patent/JOP20210227A1/ar unknown
- 2021-09-14 EC ECSENADI202167828A patent/ECSP21067828A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY38592A (es) | 2020-08-31 |
| WO2020169736A1 (en) | 2020-08-27 |
| IL285675A (en) | 2021-10-31 |
| TW202045495A (zh) | 2020-12-16 |
| EP3927696B1 (en) | 2023-10-18 |
| PH12021552018A1 (en) | 2022-09-19 |
| KR20210131371A (ko) | 2021-11-02 |
| ES2966132T3 (es) | 2024-04-18 |
| CN113474339B (zh) | 2025-02-25 |
| ECSP21067828A (es) | 2021-11-18 |
| EA202192320A1 (ru) | 2021-11-16 |
| AU2020226723A1 (en) | 2021-08-19 |
| CN113474339A (zh) | 2021-10-01 |
| EP3927696A1 (en) | 2021-12-29 |
| EP3927696C0 (en) | 2023-10-18 |
| SG11202108909SA (en) | 2021-09-29 |
| US20220127249A1 (en) | 2022-04-28 |
| US12269813B2 (en) | 2025-04-08 |
| MX2021010133A (es) | 2021-09-23 |
| JP2022523368A (ja) | 2022-04-22 |
| CA3129623A1 (en) | 2020-08-27 |
| BR112021016400A2 (pt) | 2021-10-13 |
| AU2020226723B2 (en) | 2025-01-23 |
| MA55019A (fr) | 2021-12-29 |
| JOP20210227A1 (ar) | 2021-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212067A1 (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada | |
| AR120703A1 (es) | Formas sólidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-amina de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico | |
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| PH12019501707A1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| CL2019003619A1 (es) | Preparación sólida para administración oral. | |
| DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
| MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| MX392213B (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| RU2019105794A (ru) | Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат | |
| EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
| MX2023005078A (es) | Nuevas formas cristalinas de un compuesto inhibidor de kras g12c. | |
| AR127431A1 (es) | Compuestos novedosos | |
| FI3506900T3 (fi) | Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension | |
| IL274233B1 (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| MA38697A1 (fr) | 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7 | |
| BR112016013974A8 (pt) | composto, composição farmacêutica e uso de um composto. | |
| MX2022005199A (es) | Inhibidores de ssao y uso de los mismos. |